Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Cocaine-related torsade de pointes in a methadone maintenance patient.

Krantz MJ, Rowan SB, Mehler PS.

J Addict Dis. 2005;24(1):53-60.

PMID:
15774410
2.

Methadone-induced Torsade de pointes tachycardias.

Sticherling C, Schaer BA, Ammann P, Maeder M, Osswald S.

Swiss Med Wkly. 2005 May 14;135(19-20):282-5. Review.

3.

Methadone and torsade de pointes: case report and review of the literature.

Iskandar SB, Abi-Saleh BS, Mechleb BK, Fahrig SA.

Tenn Med. 2007 Feb;100(2):35-7, 42. Review.

PMID:
17378505
4.

Prolonged QT interval and methadone: implications for palliative care.

Wilcock A, Beattie JM.

Curr Opin Support Palliat Care. 2009 Dec;3(4):252-7. doi: 10.1097/SPC.0b013e328332e0a4. Review.

PMID:
19797957
5.

Methadone and the heart: what the clinician needs to know.

George S, Moreira K, Fapohunda M.

Curr Drug Abuse Rev. 2008 Nov;1(3):297-302. Review.

PMID:
19630728
6.

Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).

Deamer RL, Wilson DR, Clark DS, Prichard JG.

J Addict Dis. 2001;20(4):7-14. Review.

PMID:
11760927
7.

Drug-induced torsade de pointes.

Raehl CL, Patel AK, LeRoy M.

Clin Pharm. 1985 Nov-Dec;4(6):675-90. Review.

PMID:
2416504
8.

QTc interval screening in methadone treatment.

Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC.

Ann Intern Med. 2009 Mar 17;150(6):387-95. Epub 2009 Jan 19.

PMID:
19153406
9.

Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.

Skanes AC, Morton BC, Green MS, Tang AS.

Can J Cardiol. 1997 Apr;13(4):383-6. Review.

PMID:
9141970
10.

Methadone-associated Q-T interval prolongation and torsades de pointes.

Stringer J, Welsh C, Tommasello A.

Am J Health Syst Pharm. 2009 May 1;66(9):825-33. doi: 10.2146/ajhp070392. Review. Erratum in: Am J Health Syst Pharm. 2010 Jan 15;67(2):94.

PMID:
19386945
11.
12.

[Drug induced QT prolongation].

Altmann D, Eggmann U, Ammann P.

Wien Klin Wochenschr. 2008;120(5-6):128-35. doi: 10.1007/s00508-008-0940-6. Review. German.

PMID:
18365152
13.

Drug therapy for torsade de pointes.

Banai S, Tzivoni D.

J Cardiovasc Electrophysiol. 1993 Apr;4(2):206-10. Review.

PMID:
8269292
15.

Drug-induced long QT syndrome and torsade de pointes.

Morissette P, Hreiche R, Turgeon J.

Can J Cardiol. 2005 Aug;21(10):857-64. Review.

PMID:
16107909
16.

Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.

Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG.

Am Heart J. 2007 Jun;153(6):891-9. Review.

PMID:
17540188
17.

Antiarrhythmic drugs and torsade de pointes.

Lazzara R.

Eur Heart J. 1993 Nov;14 Suppl H:88-92. Review.

PMID:
8293758
18.

QTc interval screening for cardiac risk in methadone treatment of opioid dependence.

Pani PP, Trogu E, Maremmani I, Pacini M.

Cochrane Database Syst Rev. 2013 Jun 20;(6):CD008939. doi: 10.1002/14651858.CD008939.pub2. Review.

PMID:
23787716
19.

Methadone death, dosage and torsade de pointes: risk-benefit policy implications.

Latowsky M.

J Psychoactive Drugs. 2006 Dec;38(4):513-9. Review.

PMID:
17373567
20.

Methadone deaths: risk factors in pain and addicted populations.

Modesto-Lowe V, Brooks D, Petry N.

J Gen Intern Med. 2010 Apr;25(4):305-9. doi: 10.1007/s11606-009-1225-0. Epub 2010 Jan 20. Review.

Items per page

Supplemental Content

Write to the Help Desk